PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trialsAug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017
This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona.
Video navigation menu
- Similarities and differences in study design of the PCSK9 inhibition CV outcome trials and (expected) results 0:27
- FOURIER: details on study design, baseline characteristics and results 3:17
- Is it surprising that no reductio in CV death was seen during the FOURIER trial? 8:02
- What can subgroup analyses tell us, including landmark analyses on those treated 2-3 years? 9:40
- How do the FOURIER resuts compare to the CTTC observations 11:36
- Additional insights on PCSK9 inhibition from the SPIRE 1&2 trials 14:51
The educational objectives of the symposium were to:
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
- Emphasize the need for outcomes data from clinical trials to apply implications and recommendations for practical lipid management
- Understand the implications of new ESC guidelines for lipid management
This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Peter Sever is Professor of Clinical Pharmacology and Therapeutics at Imperial College London and Honorary Consultant Physician at the Imperial College Healthcare NHS Trust. He is co-director of the International Centre for Circulatory Health and Head of the Physiology and Prevention Section of the National Heart and Lung Institute, Imperial College London.
This symposium was supported by unrestricted educational grant provided by Amgen and Sanofi-Regeneron
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-CME.